AEON Biopharma, Inc.
AEONAEON Biopharma, Inc. is a biotechnology company focused on developing targeted therapies for neurological and neurodegenerative disorders. The company aims to advance innovative treatments through rigorous research and clinical development, primarily targeting unmet medical needs in areas such as multiple sclerosis, stroke, and other brain-related conditions.
Company News
AEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay result...
AEON Biopharma announced the appointment of John Bencich as Chief Financial Officer on April 2, 2026, granting him 754,717 RSUs and 235,849 PSUs as inducement awards. The PSUs vest upon the company regaining NYSE American listing compliance. AEON is developing ABP-450, a biosimilar to BOTOX®, targeting the $3 billion U.S. therapeutic neurotoxin ...
AEON Biopharma announced the grant of 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025, under its 2025 Inducement Incentive Plan. The RSUs vest over four years with 25% vesting annually. The company continues development of ABP-450, a BOTOX biosimilar targeting the $3 billion U.S. therapeutic neurotoxin m...
The migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.
AEON Biopharma, a clinical-stage biopharmaceutical company, announced the closing of a $20 million public offering. The company plans to use the proceeds for general corporate purposes and working capital.
